ACE ImmunoID: End-to-End Neoantigen Discovery

ACE ImmunoID™: End-to-End Neoantigen Discovery Neoantigen selection is complex. The ACE ImmunoID Platform, which uses Personalis’ patented ACE Technology™, combines augmented exome and transcriptome sequencing with analytics to enable broad tumor immunogenomic characterization. NeoantigenID™, a component of the ACE ImmunoID platform, provides you with detailed analytics for comprehensive neoantigen [...]